Amyloid precursor protein and endosomal-lysosomal dysfunction in Alzheimer's disease: inseparable partners in a multifactorial disease
Open accessThe DOI matches its Crossref record; 216 of the 218 references it cites were found in a registry or an index.
Abstract
Abnormalities of the endosomal–lysosomal network (ELN) are a signature feature of Alzheimer's disease (AD). These include the earliest known cytopathology that is specific to AD and that affects endosomes and induces the progressive failure of lysosomes, each of which are directly linked by distinct mechanisms to neurodegeneration. The origins of ELN dysfunction and β‐amyloidogenesis closely overlap, which reflects their common genetic basis, the established early involvement of endosomes and lysosomes in amyloid precursor protein (APP) processing and clearance, and the pathologic effect of certain APP metabolites on ELN functions. Genes that promote β‐amyloidogenesis in AD (APP, PSEN1/2, and APOE4) have primary effects on ELN function. The importance of primary ELN dysfunction to pathogenesis is underscored by the mutations in more than 35 ELN‐related genes that, thus far, are known to cause familial neurodegenerative diseases even though different pathogenic proteins may be involved. In this article, I discuss growing evidence that implicates AD gene–driven ELN disruptions as not only the antecedent pathobiology that underlies β‐amyloidogenesis but also as the essential partner with APP and its metabolites that drive the development of AD, including tauopathy, synaptic dysfunction, and neurodegeneration. The striking amelioration of diverse deficits in animal AD models by remediating ELN dysfunction further supports a need to integrate APP and ELN relationships, including the role of amyloid‐β, into a broader conceptual framework of how AD arises, progresses, and may be effectively therapeutically targeted.—Nixon, R. A. Amyloid precursor protein and endosomal–lysosomal dysfunction in Alzheimer's disease: inseparable partners in a multifactorial disease. FASEB J. 31, 2729–2743 (2017). www.fasebj.org
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In summary, oxidative and/or nitrosative damage to multiple proteins, including synaptic proteins is very likely to contribute to the memory problems and other cognitive deficits, reduced ATP availability in neurons, and decreased clearance of abnormal proteins34, creating a “perfect storm” (or sTORm perhaps!) of detrimental cognitive effects in AD9,34,35,41,42.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [42]
In the citing paper
“In addition to mTOR activation, insulin resistance can also result in neuronal glucose deficiency, with consequent decreased glucose metabolism, impaired ATP production, and dysfunction and/or death7,42”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [42]
In the citing paper
“Activated mTORC1 is intimately involved in regulation of protein synthesis, autophagy, mitochondrial function, lipogenesis, ketogenesis, and insulin signaling, and is crucially linked to glucose metabolism, where it becomes activated by growth factors, amino acids, and high cellular energy status41,42 (Fig 2).”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [42]
In the citing paper
“These oxidatively modified, and likely dysfunctional, proteins include ones associated with altered glucose metabolism, mTOR signaling (including inhibited autophagy and increased insulin resistance), and the proteostasis network42,61,62,65,66.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [42]
In the citing paper
“This significant mediator of neuronal death is present in the early stages of AD, and evidence of impaired autophagy is also found in aMCI brain and PCAD brains41–43.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [42]
19 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
2 retracted
RETRACTED ARTICLE: APP binds DR6 to trigger axon pruning and neuron death via distinct caspases
Nikolaev, A., McLaughlin, T., O’Leary, D. D. M., & Tessier-Lavigne, M. (2009) · Nature · doi:10.1038/nature07767 · Cited by 992
RetractedIntegrative genomics identifies APOE ε4 effectors in Alzheimer's disease
Rhinn, H., Fujita, R., Qiang, L., Cheng, R., Lee, J. H., & Abeliovich, A. (2013) · Nature · doi:10.1038/nature12415 · Cited by 171
RetractedRepertoires of Autophagy in the Pathogenesis of Ocular Diseases
Li, Y.-J., Jiang, Q., Cao, G.-F., Yao, J., & Yan, B. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373980 · Cited by 16,304
Cui, C., Cui, J., Jin, F., Cui, Y., Li, R., Jiang, X., Tian, Y., Wang, K., Jiang, P., & Gao, J. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479571 · Cited by 5,203
The role of autophagy in neurodegenerative disease
Nixon, R. A. (2013) · Nature Medicine · doi:10.1038/nm.3232 · Cited by 2,059
Self-citationNelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., Castellani, R. J., Crain, B. J., Davies, P., Tredici, K. D., et al. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31825018f7 · Cited by 2,050
CNS synaptogenesis promoted by glia-derived cholesterol
Mauch, D. H., Nägler, K., Schumacher, S., Göritz, C., Müller, E.-C., Otto, A., & Pfrieger, F. W. (2001) · Science · doi:10.1126/science.294.5545.1354 · Cited by 1,711 · cited 1×
“Of particular relevance to AD, lipoprotein receptors mediate glia-derived cholesterol transport within the CNS, which is essential to form and maintain synapses (108).”
BackgroundExtensive Involvement of Autophagy in Alzheimer Disease: An Immuno-Electron Microscopy Study
Nixon, R. A., Wegiel, J., Kumar, A., Yu, W. H., Peterhoff, C., Cataldo, A., & Cuervo, A. M. (2005) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/64.2.113 · Cited by 1,588
Self-citationCellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers
Laurén, J., Gimbel, D. A., Nygaard, H. B., Gilbert, J. W., & Strittmatter, S. M. (2009) · Nature · doi:10.1038/nature07761 · Cited by 1,560
Lysosomal membrane permeabilization in cell death
Boya, P., & Kroemer, G. (2008) · Oncogene · doi:10.1038/onc.2008.310 · Cited by 1,426
Research works printed but not linked: 1
- 10.1111/j.1365-2990.2010.01062.x · doi:10.1111/j.1365-2990.2010.01062.x · Paper page
Cited by
Items 101–200 of 407
Argueti-Ostrovsky, S., Alfahel, L., Kahn, J., & Israelson, A. (2021) · Cells · doi:10.3390/cells10092438 · Cited by 48
Rudajev, V., & Novotný, J. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01127-y · Cited by 54
Liu, Z., Wang, Q., Zhu, Z., Liu, M., Zhao, X., & Zhu, W. (2020) · Chemical Science · doi:10.1039/d0sc04156d · Cited by 44
Current research status of blood biomarkers in Alzheimer’s disease: Diagnosis and prognosis
Feng, L., Li, J., & Zhang, R. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101492 · Cited by 47
Daly, J. L., Danson, C. M., Lewis, P. A., Zhao, L., Riccardo, S., Di Filippo, L., Cacchiarelli, D., Lee, D., Cross, S. J., Heesom, K. J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38719-8 · Cited by 45
“APP mis-processing and accumulation within the endo-lysosomal network is a crucial hallmark of Alzheimer ’ s disease, and is suf fi cient to induce lysosomal dysfunction 45 .”
Jung, Y. H., Chae, C. W., & Han, H. J. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-024-01282-3 · Cited by 49
“…the regulatory mechanisms of endosomal abnormalities and lysosomal impairment in the pathogenesis of AD are endolysosomal protein-mediated abnormal processing mediated by endolysosomal proteins of amyloid precursor protein (APP) and impaired degradation of A β and hyperpho-sphorylated tau 27,28 .”
BackgroundP38α MAPK Signaling—A Robust Therapeutic Target for Rab5-Mediated Neurodegenerative Disease
Germann, U. A., & Alam, J. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155485 · Cited by 44
“Taken together, overactivated Rab5 and subsequent endo-lysosomal dysfunction have emerged as a major driving force of degenerative and cognitive deficits during the development of AD [1,48,71,79] and alterations in Rab5 also seem to play an important role in other types of neurodegenerative diseases [52,71].”
BackgroundInfluentialGautier, M. K., & Ginsberg, S. D. (2020) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2020.109038 · Cited by 48
“Endocytic trafficking defects have been described in many neurodegenerative disorders, including Alzheimer’s disease (AD) (Perez et al., 2015; Nixon, 2017), Huntington’s disease (Kegel et al., 2000; Pal et al., 2006; Malik et al., 2019), amyotrophic lateral sclerosis (Mitra et al., 2019),…”
BackgroundSanchez-Varo, R. M., Sánchez‐Mejías, E., Fernandez-Valenzuela, J. J., Castro, V. D., Mejias‐Ortega, M., Gómez-Arboledas, Á., Jiménez, S., Sanchez-Mico, M. V., Trujillo‐Estrada, L., Moreno‐González, I., et al. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.752594 · Cited by 43
“…AD brains (Plowey and Wiley, 2007; Nixon et al., 2008; Tramutola et al., 2015) and models (Majumder et al., 2011; Steele et al., 2013; Yang et al., 2008, 2011), indicating that endolysosomal autophagy deficiencies play a role in AD and amyloidogenesis (for review see Nixon, 2017; Cao et al., 2019).”
BackgroundDown syndrome and Alzheimer's disease: insights into biomarkers, clinical symptoms, and pathology
Rafii, M. S., Schlachetzki, Z., Barroeta, I., Head, E., Fortea, J., & Ances, B. M. (2025) · The Lancet Neurology · doi:10.1016/s1474-4422(25)00237-6 · Cited by 54
The dense-core plaques of Alzheimer’s disease are granulomas
Lemke, G., & Huang, Y. (2022) · Journal of Experimental Medicine · doi:10.1084/jem.20212477 · Cited by 37
“This hypothesis aligns with an established role for lysosomal dysfunction in AD (Nixon, 2017; Whyte et al., 2017).”
BackgroundFinding memo: versatile interactions of the VPS10p-Domain receptors in Alzheimer’s disease
Salasova, A., Monti, G., Andersen, O. M., & Nykjaer, A. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00576-2 · Cited by 42
Endosomal-Lysosomal Processing of Neurodegeneration-Associated Proteins in Astrocytes
Wong, C.-O. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21145149 · Cited by 31
Wilkins, H., Troutwine, B., Menta, B. W., Manley, S., Strope, T., Lysaker, C., & Swerdlow, R. H. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215280 · Cited by 41
“This is potentially relevant because endosomes move A (cid:2) PP through the cell [43, 44], genetic studies implicate a role for endosome function in AD [45], and mitochondria influence endosome pathway dynamics [46].”
Association Between Atg5-independent Alternative Autophagy and Neurodegenerative Diseases
Honda, S., Arakawa, S., Yamaguchi, H., Torii, S., Sakurai, H. T., Tsujioka, M., Murohashi, M., & Shimizu, S. (2020) · Journal of Molecular Biology · doi:10.1016/j.jmb.2020.01.016 · Cited by 36
Lee, Y., Miller, M. R., Fernandez, M. A., Berg, E. L., Prada, A. M., Ouyang, Q., Schmidt, M., Silverman, J. L., Young-Pearse, T. L., & Morrow, E. M. (2022) · Brain · doi:10.1093/brain/awab467 · Cited by 35
Gebril, H. M., Aryasomayajula, A., de Lima, M. R. N., Uhrich, K. E., & Moghe, P. V. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-023-00393-7 · Cited by 40
Santoni, G., Maggi, F., Amantini, C., Marinelli, O., Nabissi, M., & Morelli, M. B. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00251 · Cited by 41
“TRPML1 can also be negatively regulated through the phosphorylation of Ser572 and Ser576 residues by the target of rapamycin (TOR) with a consequent autophagy decrease (Onyenwoke et al., 2015).”
BackgroundMultifaceted Alzheimer’s Disease: Building a Roadmap for Advancement of Novel Therapies
Kaur, D., Behl, T., Sehgal, A., Singh, S., Sharma, N., & BUNGAU, S. G. (2021) · Neurochemical Research · doi:10.1007/s11064-021-03415-w · Cited by 35
Wakhloo, D., Mahajani, S. U., Oberhauser, J., & Madira, A. E. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.336138 · Cited by 42
“NSCs can also differentiate into certain glial cells such as astrocytes and oligodendrocytes (Kriegstein and Alvarez-Buylla, 2009; Mahajani et al., 2014, 2017).”
Neuro-protective effects of aloperine in an Alzheimer’s disease cellular model
Zhao, J., Zhang, G., Li, M., Luo, Q., Leng, Y., & Liu, X. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.09.008 · Cited by 37
Moya‐Alvarado, G., Guerra, M. V., Tiburcio, R., Bravo, E., & Bronfman, F. C. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105796 · Cited by 36
Cathepsin D: Analysis of its potential role as an amyloid beta degrading protease
Gallwitz, L., Schmidt, L., Marques, A. R. A., Tholey, A., Cassidy, L., Ulku, I., Multhaup, G., Spiezio, A. D., & Säftig, P. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105919 · Cited by 38
“It has been realized that autophagic/lysosomal dysfunction and deficient lysosomal proteolysis contribute to the development of AD [27].”
BackgroundAlexandrov, P. N., Zhao, Y., Jaber, V. R., Cong, L., & Lukiw, W. J. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00670 · Cited by 36
Leparulo, A., Mahmud, M., Scremin, E., Pozzan, T., Vassanelli, S., & Fasolato, C. (2019) · Cells · doi:10.3390/cells9010054 · Cited by 33
Kessissoglou, I. A., Langui, D., Hasan, A., Maral, M., Dutta, S. B., Hiesinger, P. R., & Hassan, B. A. (2020) · PLoS Biology · doi:10.1371/journal.pbio.3000703 · Cited by 35
APP-Mediated Signaling Prevents Memory Decline in Alzheimer’s Disease Mouse Model
Deyts, C., Clutter, M., Pierce, N., Chakrabarty, P., Ladd, T. B., GODDI, A. A., Rosario, A. M., Cruz, P. E., Vetrivel, K. S., Wagner, S. L., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.03.087 · Cited by 32
“Indeed, APP processing has intricate connections with the endo/lysosomal network (Nixon, 2017; Wang et al., 2018).”
BackgroundElder, M. K., Erdjument‐Bromage, H., Oliveira, M. M., Mamcarz, M., Neubert, T. A., & Klann, E. (2021) · Communications Biology · doi:10.1038/s42003-021-02324-6 · Cited by 40
Srivastava, A. K., Flint, N., Kreckel, H. D., Gryzik, M., Poli, M., Arosio, P., & Bou‐Abdallah, F. (2020) · Biochemistry · doi:10.1021/acs.biochem.0c00246 · Cited by 30
Wang, Y., Wu, Q., Anand, B. G., Karthivashan, G., Phukan, G., Yang, J., Thinakaran, G., Westaway, D. A., & Kar, S. (2020) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12647 · Cited by 33
Guix, F. X. (2019) · Journal of Neuroscience Research · doi:10.1002/jnr.24526 · Cited by 31
“Enlarged endosomes are observed in pyramidal neurons of the neocortex of AD patients at preclinical stages of the disease (Cataldo et al., 2000; Nixon, 2017).”
BackgroundCrossroads between membrane trafficking machinery and copper homeostasis in the nerve system
Wen, M., Xie, X., Huang, P.-S., Yang, K., & Chen, T. (2021) · Open Biology · doi:10.1098/rsob.210128 · Cited by 32
“org 9 the failure of clearance for amyloid proteins in the brain and the accumulation of toxic protein aggregates over time [149].”
BackgroundAutophagy system as a potential therapeutic target for neurodegenerative diseases
Cui, M., Yoshimori, T., & Nakamura, S. (2022) · Neurochemistry International · doi:10.1016/j.neuint.2022.105308 · Cited by 29
Bhattacharyya, R., Teves, C. A. F., Long, A., Hofert, M., & Tanzi, R. E. (2022) · Scientific Reports · doi:10.1038/s41598-022-07372-4 · Cited by 36
Lei, M., Teo, J. D., Song, H., McEwen, H. P., Yup Lee, J., Couttas, T. A., Duncan, T., Chesworth, R., Bertz, J., Przybyla, M., et al. (2019) · The Journal of Neuroscience · doi:10.1523/jneurosci.0524-19.2019 · Cited by 27
“A strong body of genetic and neuropathological evidence implicates both impaired cellular cholesterol metabolism and altered endosomal membrane composition and trafficking in the etiology of AD (Morel et al., 2013; Karch and Goate, 2015; Nixon, 2017; Nuriel et al., 2017).”
BackgroundQureshi, Y. H., Baez, P., & Reitz, C. (2020) · Molecular and Cellular Biology · doi:10.1128/mcb.00262-20 · Cited by 25
Melman, A., & Bou‐Abdallah, F. (2020) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2020.129700 · Cited by 29
Alcantara‐Gonzalez, D., Chartampila, E., Criscuolo, C., & Scharfman, H. E. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105274 · Cited by 27
Role of endolysosomes and inter-organellar signaling in brain disease
Afghah, Z., Chen, X., & Geiger, J. D. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104670 · Cited by 28
Jaye, S., Sandau, U. S., & Saugstad, J. A. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1378576 · Cited by 26
“These defects then result in various neuropathological outcomes such as A β 1-42 over production and clearance deficits, as well as dystrophic neurites (Nixon, 2017; Colacurcio et al., 2018; Szabo et al., 2022).”
Impaired autophagy in amyloid-beta pathology: A traditional review of recent Alzheimer's research
Yuan, M., Wang, Y., Huang, Z., Jing, F., Qiao, P., Zou, Q., Li, J., & Cai, Z. (2022) · Journal of Biomedical Research · doi:10.7555/jbr.36.20220145 · Cited by 27
Jensen, A. M. G., Raska, J., Fojtik, P., Monti, G., Lunding, M., Bartova, S., Pospisilova, V., van der Lee, S. J., Van Dongen, J., Bossaerts, L., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2408262121 · Cited by 22
“More recently, disease - causing variants of these genes, when modeled in iPSC - derived neurons, also phenocopy the defining cytopathology of AD ( 3 ), which is endosome enlargement ( 4 , 5 ).”
Endosomal Acid-Base Homeostasis in Neurodegenerative Diseases
Prasad, H., & Rao, R. (2020) · Reviews of physiology, biochemistry and pharmacology · doi:10.1007/112_2020_25 · Cited by 26
Valverde, A., Dunys, J., Lorivel, T., Debayle, D., Gay, A.-S., Caillava, C., Chami, M., & Checler, F. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100963 · Cited by 24
“In AD mouse models, several anatomical and functional paradigms including apathy-like phenotype, long term potentiation perturbation, and endolysosomal dysfunction (9, 44, 45) have been shown to occur early and independently of Aβ (7, 46) and, for some of them, are drastically potentiated by γsecretase inhibitors (7).”
BackgroundOatman, S. R., Reddy, J. S., Quicksall, Z., Carrasquillo, M. M., Wang, X., Liu, C., Yamazaki, Y., Nguyen, T., Malphrus, K. G., Heckman, M. G., et al. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00592-2 · Cited by 29
Focusing on cellular biomarkers: The endo-lysosomal pathway in Down syndrome
Botté, A., & Potier, M. (2019) · Progress in brain research · doi:10.1016/bs.pbr.2019.10.002 · Cited by 25
Roque, C. G., Chung, K. M., McCurdy, E. P., Jagannathan, R., Randolph, L. K., Herline, K., Baleriola, J., & Hengst, U. (2023) · Science Advances · doi:10.1126/sciadv.add2671 · Cited by 28
Lysosomal enzyme activities as possible CSF biomarkers of synucleinopathies
Paciotti, S., Gatticchi, L., Beccari, T., & Parnetti, L. (2019) · Clinica Chimica Acta · doi:10.1016/j.cca.2019.03.1627 · Cited by 26
Neurosteroids and Oxysterols as Potential Therapeutic Agents for Glaucoma and Alzheimer’s Disease
Ishikawa, M., Yoshitomi, T., Covey, D. F., Zorumski, C. F., & Izumi, Y. (2018) · Neuropsychiatry · doi:10.4172/neuropsychiatry.1000356 · Cited by 23
Kim, H., Seo, B.-R., Kim, H., & Koh, J. (2020) · Scientific Reports · doi:10.1038/s41598-020-66292-3 · Cited by 25
Jang, J., Yeo, S., Baek, S., Jung, H. J., Lee, M. S., Choi, S. H., & Choe, Y. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01637-3 · Cited by 20
“While there has been recent research on outside-in signaling in the development of DNs [54], we believe this is the first study of inside-out vesicles affecting DNs in AD.”
BackgroundResultDougnon, G., & Matsui, H. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00529-x · Cited by 27
Exosome release and cargo in Down syndrome
Hamlett, E. D., LaRosa, A., Mufson, E. J., Fortea, J., Ledreux, A., & Granholm, A. (2019) · Developmental Neurobiology · doi:10.1002/dneu.22712 · Cited by 22
“Since the autophagosome and other degradation pathways are disrupted in both AD and DS (Colacurcio et al., 2018; Nixon, 2017; Tramutola et al., 2016; Uddin et al., 2018), Aβ may accumulate and propagate by disrupting the normal degradation of amyloid peptides.”
BackgroundMechanistic Analysis of Age-Related Clinical Manifestations in Down Syndrome
Chen, X., Xing, Z., Chen, Q.-D., Salvi, R., Zhang, X., Tycko, B., Mobley, W. C., & Yu, Y. E. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.700280 · Cited by 26
“Finally, there is evidence pointing to lysosome-autophagy deficits in DS (reviewed in Nixon, 2017; Colacurcio et al., 2018).”
BackgroundTsourmas, K. I., Butler, C. A., Kwang, N. E., Sloane, Z. R., Dykman, K. J. G., Maloof, G. O., Choudhury, B., Paulchakrabarti, M., Prekopa, C. A., Tabaie, E. Z., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63237-0 · Cited by 25
“Neurons and microglia/myeloid cells from Hexb -/- mice both had signi fi cantly higher expression of several proteins associated with dysregulation of the endosomal-lysosomal system compared to WT cells, including APOE and cathepsin B 102 – 105 .”
Du, M., Yu, Y., Wang, J., & Ji, C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms27010366 · Cited by 27
“Phosphorylation at key residues such as Thr181 and Thr217 markedly increases tau’s resistance to lysosomal proteolysis through its proline-rich domain, and this resistance intensifies with elevated lysosomal pH [55].”
Endosome Dysregulation in Down Syndrome: A Potential Contributor to Alzheimer Disease Pathology
Filippone, A., & Praticò, D. (2021) · Annals of Neurology · doi:10.1002/ana.26042 · Cited by 20
“frequently already detected at the fetal stage (28 weeks of gestation).(26) Although morphological changes in the endosomes have been found in postmortem brain tissues of DS patients and in the CNS of Ts65Dn mice (a transgenic mouse model of DS),(27) enlarged endosomes are also observed in the periphery, such as blood…”
BackgroundExploring the potential role of rab5 protein in endo-lysosomal impairment in Alzheimer’s disease
Behl, T., Kaur, D., Sehgal, A., Singh, S., Makeen, H. A., Albratty, M., Abdellatif, A. A. H., Dachani, S. R., & BUNGAU, S. G. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112773 · Cited by 21
Epithelial Transport in Disease: An Overview of Pathophysiology and Treatment
Clemente‐Suárez, V. J., Martín-Rodríguez, A., Redondo-Flórez, L., Villanueva-Tobaldo, C. V., Sepulveda, R. A. Y., & Tornero-Aguilera, J. F. (2023) · Cells · doi:10.3390/cells12202455 · Cited by 28
“For example, defects in vesicular transport have been implicated in neurological disorders such as Alzheimer’s disease and Parkinson’s disease [23,24].”
BackgroundHe, H., Cao, X., Yin, F., Wu, T., Stauber, T., & Peng, J. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02291-3 · Cited by 25
Membrane interaction to intercellular spread of pathology in Alzheimer’s disease
Valappil, D. K., Mini, N. J., Dilna, A., & Nath, S. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.936897 · Cited by 19
“C-terminal cleavage between 40 and 42 hydrophobic residues is responsible for strong hydrophobicity in Aβ peptides (Nixon, 2017).”
BackgroundMüller-Thomsen, L., Borgmann, D., Morcinek, K., Schröder, S. L., Dengler, B., Moser, N., Neumaier, F., Schneider, T., Schröder, H., & Huggenberger, S. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.03.007 · Cited by 22
Chae, C. W., Lee, H. J., Choi, G. E., Jung, Y. H., Kim, J. S., Lim, J. R., Kim, S. Y., Hwang, I. K., Seong, J. K., & Han, H. J. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15131 · Cited by 19
“Consistent with our results, early endosomal enlargement was reported in diabetic monkey brain, which up-regulated Aβ production (Okabayashi et al., 2015).”
ResultWhen lipid homeostasis runs havoc: Lipotoxicity links lysosomal dysfunction to autophagy
Tegeder, I., & Kögel, D. (2020) · Matrix Biology · doi:10.1016/j.matbio.2020.11.005 · Cited by 22
Nie, L., Zhang, Y., Li, L., van Rijn, P., & Schirhagl, R. (2021) · Nanomaterials · doi:10.3390/nano11071837 · Cited by 20
“In the recent decades, nanoscale carriers show great potential in endolysosomes targeting for treating cancer [34,41] Alzheimer’s disease (ADs) [42], Parkinson’s disease [43], and lysosomal storage diseases [44].”
BackgroundParkin as a Molecular Bridge Linking Alzheimer’s and Parkinson’s Diseases?
Checler, F., & da Costa, C. A. (2022) · Biomolecules · doi:10.3390/biom12040559 · Cited by 19
Endosomal trafficking and related genetic underpinnings as a hub in Alzheimer's disease
Limone, A., Veneruso, I., D’Argenio, V., & Sarnataro, D. (2022) · Journal of Cellular Physiology · doi:10.1002/jcp.30864 · Cited by 18
“Indeed, the ApoE ε4 isoform has been related to a reduced endosomal recycling and increased endocytosis of both APP and BACE1 (He et al., 2007; Nixon, 2017).”
BackgroundAmyloid‐β in Alzheimer's disease: Structure, toxicity, distribution, treatment, and prospects
Yu, Y., Yu, S., Battaglia, G., & Tian, X. (2024) · Ibrain · doi:10.1002/ibra.12155 · Cited by 38
“12,41 In addition, A β disrupted the endocytic trafficking of plasma membrane receptors, damaging glutamatergic neurons and primary rat cortical neurons.”
BackgroundAn inorganic overview of natural Aβ fragments: Copper(II) and zinc(II)-mediated pathways
Lanza, V., Bellia, F., & Rizzarelli, E. (2018) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2018.04.004 · Cited by 21
Lysosomal Dysregulation in the Murine App Model of Alzheimer’s Disease
Whyte, L. S., Hassiotis, S., Hattersley, K. J., Hemsley, K. M., Hopwood, J. J., Lau, A. A., & Sargeant, T. J. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2019.12.042 · Cited by 22
Snatched from oblivion: “second lives” of bespoke drugs
Pederson, T. (2020) · The FASEB Journal · doi:10.1096/fj.201902914 · Cited by 19
Tangles and Plaques: A deep dive into the pathological hallmarks of Alzheimer’s disease
Vanya, Kumari, S., Bagri, K., & Deshmukh, R. R. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.10.050 · Cited by 19
AP2S1 regulates APP degradation through late endosome–lysosome fusion in cells and APP / PS1 mice
Wen, Q., Luo, B., Xie, X., Zhou, G., Chen, J., Li, S., Liu, Y., Xie, S., Chen, L., Li, K., et al. (2022) · Traffic · doi:10.1111/tra.12874 · Cited by 20
“Amyloid precursor protein (APP) is the only source of β-amyloid peptide (Aβ), which forms the characteristic amyloid plaques in Alzheimer disease (AD).1 The proteolytic cleavage of APP involves the enzymatic activity of β-site APP cleaving enzyme 1 (BACE1) and γ-secretase, leading to the generation of the N-terminal s…”
BackgroundInfluentialModelling Alzheimer's disease using human brain organoids: current progress and challenges
Yanakiev, M., Soper, O., Berg, D. A., & Kang, E. (2022) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2022.40 · Cited by 18
Experimental approaches for altering the expression of Abeta‐degrading enzymes
Loeffler, D. A. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15762 · Cited by 20
“The main degradation mechanisms are the endosomal– lysosomal system (Nixon, 2017), the ubiquitin– proteasome system (Hong et al., 2014), and autophagy (Cho et al., 2014).”
BackgroundAdvancements in autophagy perturbations in Alzheimer’s disease: Molecular aspects and therapeutics
Dhapola, R., Kumari, S., Sharma, P., Vellingiri, B., & HariKrishnaReddy, D. (2025) · Brain Research · doi:10.1016/j.brainres.2025.149494 · Cited by 17
Kaur, G., Gauthier, S. A., Pérez‐González, R., Pawlik, M., Singh, A. B., Cosby, B., Mohan, P. S., Smiley, J. F., & Levy, E. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.08.025 · Cited by 18
“…protein (APP), located on HSA21 (Kang et al., 1987), that results in the overexpression of APP and APP metabolites, contributes to endosomal disruption in neurons (Cataldo et al., 2001; Choi, 1988; Jiang et al., 2016; Nixon, 2017; Xu et al., 2016) and non-neuronal cells (Jiang et al., 2010).”
BackgroundDefective Lysosomal Lipid Catabolism as a Common Pathogenic Mechanism for Dementia
Lee, J. Y., Marian, O. C., & Don, A. S. (2021) · NeuroMolecular Medicine · doi:10.1007/s12017-021-08644-4 · Cited by 20
“2005), together with aberrant overactivation of rab5, a small GTPase that is crucial for the regulation of endosomal trafficking, maturation, and cycling (Nixon 2017).”
BackgroundSun, Y., Wang, Y., Guo, Z., Du, K., & Meng, D. (2019) · Molecules · doi:10.3390/molecules24081499 · Cited by 17
“Compound–Target Network Multifactorial mechanisms of AD have been proposed previously, which indicated that more than one hypothesis is involved in the pathogenesis of AD, such as amyloid cascade, tau, neuroinflammation, oxidative stress, and glutamate system dysfunction [19,20].”
BackgroundInfluentialKomatsu, A., Iida, I., Nasu, Y., Ito, G., Harada, F., Kishikawa, S., Moss, S. J., Maeda, T., & Terunuma, M. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.101933 · Cited by 16
“In addition, abnormalities of the endolysosomal and autophagy system are reported in AD (57), and APP processing and A β production are found to be regulated by the endolysosomal system (58).”
Engineered Antibodies to Improve Efficacy against Neurodegenerative Disorders
Niazi, S. K., Mariam, Z., & Magoola, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126683 · Cited by 17
“It is broken down by the endosomal-lysosomal system [88], the ubiquitin–proteasome system [89], and autophagy [90].”
BackgroundImpact of Autophagy and Aging on Iron Load and Ferritin in Drosophila Brain
Jacomin, A., Geraki, K., Brooks, J., Tjhin, V. T., Collingwood, J. F., & Nezis, I. P. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00142 · Cited by 17
“As expected, Atg8a expressing is reduced in old wild-type flies (Simonsen et al., 2008; Omata et al., 2014).”
BackgroundEckman, E. A., Clausen, D. M., Solé‐Domènech, S., Lee, C. W., Pereira, C. S., Domalewski, R. J., Nichols, M. R., & Pacheco‐Quinto, J. (2023) · Journal of Neuroscience · doi:10.1523/jneurosci.1318-23.2023 · Cited by 16
Plasma phosphorylated-tau217 is increased in Niemann–Pick disease type C
González‐Ortiz, F., Karikari, T. K., Vruchte, D. T., Shepherd, D., Kirsebom, B., Fladby, T., Platt, F. M., & Blennow, K. (2024) · Brain Communications · doi:10.1093/braincomms/fcae375 · Cited by 18
Martá-Ariza, M., Leitner, D. F., Kanshin, E., Suazo, J., Giusti Pedrosa, A., Thierry, M., Lee, E. B., Devinsky, O., Drummond, E., Fortea, J., et al. (2025) · Acta Neuropathologica · doi:10.1007/s00401-025-02844-z · Cited by 15
Lysosomal gene Hexb displays haploinsufficiency in a knock-in mouse model of Alzheimer’s disease
Whyte, L. S., Fourrier, C., Hassiotis, S., Lau, A. A., Trim, P. J., Hein, L. K., Hattersley, K. J., Bensalem, J., Hopwood, J. J., Hemsley, K. M., et al. (2022) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2022.01.004 · Cited by 14
“Examination of the AD brain reveals enlarged rab5-positive endosomes (Cataldo et al., 2000; Nixon, 2017) and dystrophic axons filled with lysosomal network cargo vesicles around Aβ plaques (Nixon et al., 2005; Terry et al., 1964).”
BackgroundInfluentialSNARE proteins rescue impaired autophagic flux in Down syndrome
Aivazidis, S., Jain, A., Rauniyar, A. K., Anderson, C. C., Marentette, J., Orlicky, D. J., Fritz, K. S., Harris, P. S., Siegel, D. M., Maclean, K. N., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0223254 · Cited by 13
Imaging Endocytosis Dynamics in Health and Disease
Tagliatti, E., & Cortese, K. (2022) · Membranes · doi:10.3390/membranes12040393 · Cited by 18
“Such mutations can impact AD in multiple ways: for example, by affecting neuron ability in degrading β amyloid or by directly affecting synaptic function [68].”
BackgroundSukreet, S., Rafii, M. S., & Rissman, R. A. (2024) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12580 · Cited by 17
Chen, X., Becker, A., Albay, R., Nguyen, P. D., Karachentsev, D., Roberts, A. J., Rynearson, K. D., Tanzi, R. E., & Mobley, W. C. (2024) · Annals of Neurology · doi:10.1002/ana.26958 · Cited by 16
“35,36 In AD and DS models, increased levels of β -CTF have been shown to induce Rab5 hyperactivation, 14,37 but whether A β peptides play a role in the hyperactivation of Rab5 has not been de fi ned.”
He, B., Perez, S. E., Lee, S. H., Ginsberg, S. D., Malek‐Ahmadi, M. H., & Mufson, E. J. (2020) · The Journal of Comparative Neurology · doi:10.1002/cne.24929 · Cited by 15
“Numerous studies indicate the EL system plays a key role in amyloid-β precursor protein (APP) processing and Aβ generation in AD (Nixon, 2007, 2017; Pasternak, Callahan, & Mahuran, 2004).”
BackgroundDegradation Products of Amyloid Protein: Are They The Culprits?
Zaretsky, D. V., & Zaretskaia, M. V. (2020) · Current Alzheimer Research · doi:10.2174/1567205017666201203142103 · Cited by 15
LAMP2 deficiency attenuates the neurodegeneration markers induced by HSV-1 infection
Kristen, H., Sastre, I., Aljama, S., Fuentes, M., Recuero, M., Frank, A., Martín, Á. G., Sánchez‐Juan, P., Lage, C., Bullido, M. J., et al. (2021) · Neurochemistry International · doi:10.1016/j.neuint.2021.105032 · Cited by 14
The triggering receptor expressed on myeloid cells 2–apolipoprotein E signaling pathway in diseases
Lyu, S., Lan, Z., & Li, C. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002167 · Cited by 15
“Impaired synaptic function is a pathological feature of many neurodegenerative diseases, including Alzheimer’s disease (AD).([47,48]) At the same time, more and more evidence shows that changes inApoE subtypes can affect its function and change the integrity and plasticity of synapses.”
BackgroundMishra, S., Jayadev, S., & Young, J. E. (2024) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2022.0389 · Cited by 15
Pollack, S. J., Dakkak, D., Guo, T., Chennell, G., Gomez-Suaga, P., Noble, W., Jimenez-Sanchez, M., & Hanger, D. P. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05337-6 · Cited by 14
“Disrupted endosomal protein expression has been reported within neurons in AD, with increasing evidence that disruption in endosomal trafficking is an early defect in AD [51].”
BackgroundMoss, D. E., & Perez, R. G. (2024) · Journal of Alzheimer s Disease · doi:10.1177/13872877241289602 · Cited by 16
Yamamoto, K., Yamamoto, R., & Kato, N. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.660319 · Cited by 15
“…a part of large-scale signaling system such as synaptic regulation, lysosome/endosome network functioning, protein internalization, and lipid transport (Deyts et al., 2016; Bukhari et al., 2017; Guénette et al., 2017; Müller et al., 2017; Nixon, 2017; Jiang et al., 2019; Montesinos et al., 2020).”
BackgroundTargeting lysosome function causes selective cytotoxicity in VHL-inactivated renal cell carcinomas
Bouhamdani, N., Comeau, D., Coholan, A., Cormier, K., & Turcotte, S. (2019) · Carcinogenesis · doi:10.1093/carcin/bgz161 · Cited by 14
“Among the 84 genes tested, the most up-regulated mRNAs were genes with roles in lysosome integrity and/or lysosome maturation and fusion; CTSD, NPC1, CTSB, CTSS, GAA, GABARAP, UVRAG and APP (Figure 3A) (26,27).”
BackgroundChen, X., Sawa, M., Becker, A., Karachentsev, D., Zuo, X., Rynearson, K. D., Tanzi, R. E., & Mobley, W. C. (2023) · Annals of Neurology · doi:10.1002/ana.26659 · Cited by 13
“If increased APP dose was proven necessary, this would motivate studies to elucidate which APP product(s) acts and point to therapeutic options for preventing retromer dysfunction in DS.”
BackgroundInfluential
Metadata
- Authors
- Nixon, R. A.
- Affiliations
- Nathan Kline Institute for Psychiatric Research (US)
- Corresponding author
- Nixon, Ralph A.
- ORCID
- Nixon, Ralph A.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2017-06-14
- Volume
- 31
- Issue
- 7
- Pages
- 2729-2743
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- PMC
- PMC6137496
- OpenAlex
- W2728546490
- Cited by
- 400
- References
- 218
- Citations by year
- 2026: 39 · 2025: 55 · 2024: 44 · 2023: 36 · 2022: 50 · 2021: 55 · 2020: 55 · 2019: 34 · 2018: 25 · 2017: 7
- FWCI
- 4.06
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- The FASEB Journal (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- Funders
- National Institutes of Health
- National Institute on Aging
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular transport and secretion
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
- Keywords
- Alzheimer's disease, amyloid precursor protein, lysosomal dysfunction, endosomes, APP processing, presenilin 1, presenilin 2, APOE ε4, tauopathy, synaptic dysfunction, neurodegeneration, familial neurodegenerative disease, animal models of Alzheimer's disease, therapeutic target
- MeSH terms
- Alzheimer Disease, Gene Expression Regulation, Humans, Lysosomes, Endosomes, Amyloid beta-Protein Precursor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.